Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide

American Journal of Respiratory Cell and Molecular Biology

Volumn 41, Issue 1, 2009, Pages 100-106

  Guilbault, Claudine ^a   Wojewodka, Gabriella ^a   Saeed, Zienab ^a   Hajduch, Marian ^b   Matouk, Elias ^c   De Sanctis, Juan B ^d   Radzioch, Danuta ^a,e  

^a MCGILL UNIVERSITY   (Canada)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^e MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Arachidonic acid; Ceramide; Cystic fibrosis; Docosahexaenoic acid; Fenretinide

Indexed keywords

ARACHIDONIC ACID; CERAMIDE; DOCOSAHEXAENOIC ACID; FENRETINIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG EFFECT; ESSENTIAL FATTY ACID DEFICIENCY; FATTY ACID BLOOD LEVEL; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; WILD TYPE; ADOLESCENT; ANIMAL; BLOOD; CASE CONTROL STUDY; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MOUSE; DISEASE MODEL; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; ILEUM; LIVER; LUNG; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PANCREAS; PATHOGENICITY; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

MUS;

ADOLESCENT; ADULT; AGED; ANIMALS; ARACHIDONIC ACID; CASE-CONTROL STUDIES; CERAMIDES; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; FEMALE; FENRETINIDE; FORCED EXPIRATORY VOLUME; HUMANS; ILEUM; LIVER; LUNG; MALE; MICE; MICE, INBRED CFTR; MIDDLE AGED; PANCREAS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 67649172232     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2008-0279OC     Document Type: Article

References (30)

1. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008;3:279-312.
2. Moyad MA. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part I. Urol Oncol 2005;23:28-35.
3. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, Weed DA, Gelrud A, Regan MM, Laposata M, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-569.
4. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in Cftr(-/-) mice. Proc Natl Acad Sci USA 1999;96:13995-14000.
5. Al-Turkmani MR, Freedman SD, Laposata M. Fatty acid alterations and N-3 fatty acid supplementation in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 2007;77:309-318.
6. Saeed Z, Guilbault C, De Sanctis JB, Henri J, Marion D, St-Arnaud R, Radzioch D. Fenretinide prevents the development of osteoporosis in Cftr-KO mice. J Cyst Fibros 2008;7:222-230.
7. Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, Skinner TA, Vilela RM, Kubow S, Lands LC, Hajduch M, et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol 2008;38:47-56.
8. Grassme H, Jendrossek V, Riehle A, von Kurthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003;9:322-330.
9. Rodman DM, Polis JM, Heltshe SL, Sontag MK, Chacon C, Rodman RV, Brayshaw SJ, Huitt GA, Iseman MD, Saavedra MT, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005;171:621-626.
10. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest 2004;125:1S-39S.
11. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
12. American Thoracic Society. Standardization of spirometry: update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987;136:1285-1298.
13. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-734.
14. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2005;172:885-891.
15. Guilbault C, Martin P, Houle D, Boghdady ML, Guiot MC, Marion D, Radzioch D. Cystic fibrosis lung disease following infection with Pseudomonas aeruginosa in the Cftr knockout mice using novel noninvasive direct pulmonary infection technique. Lab Anim 2005;39:336-352.
16. Guilbault C, Novak JP, Martin P, Boghdady ML, Saeed Z, Guiot MC, Hudson TJ, Radzioch D. Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared with their littermate controls. Physiol Genomics 2006;25:179-193.
17. VanHandel E, Zilversmith DB. Micromethod for the direct determination of serum triglycerides. J Lab Clin Med 1957;50:152-157.
18. Folch J, Lees M, Sloane Stanely GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497-509.
19. Ichioka T, Uobe K, Stoskopf M, Kishimoto Y, Tennekoon G, Tourtellotte WW. Anti-galactocerebroside antibodies in human cerebrospinal fluids determined by enzyme-linked immunosorbent assay (ELISA). Neurochem Res 1988;13:203-207.
20. Thuillier Y, Lubetzki C, Goujet-Zalc C, Galli A, Lhermitte F, Zalc B. Immunological determination of galactosylceramide level in blood as a serum index of active demyelination. J Neurochem 1988;51:380-384.
21. Calder PC. N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505S-1519S.
22. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 2008;233:674-688.
23. Kim YJ, Takahashi R. Role of polyunsaturated fatty acids for misfolding protein aggregations: implication for neurodegenerative diseases. Ann N Y Acad Sci 2006;1086:11-20.
24. Moyad MA. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part II. Urol Oncol 2005;23:36-48.
25. Savtchouk IA, Mattie FJ, Ollis AA. Ceramide: from embryos to tumors. Sci STKE 2007;394:jc1.
26. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 2008.
27. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008;14:382-391.
28. Camerini T, Mariani L, De PG, Marubini E, Di Mauro MG, Decensi A, Costa A, Veronesi U. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 2001;19:1664-1670.
29. Veronesi U, De PG, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999;91:1847-1856.
30. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De BB, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003;9:2032-2039.